Pemvidutide: Altimmune's MASH-Focused GLP-1 / Glucagon Dual

What pemvidutide is

Pemvidutide (formerly ALT-801) is a synthetic peptide that activates two receptors: the GLP-1 receptor and the glucagon receptor. It is developed by Altimmune, a small US biotechnology company.

Structurally, pemvidutide is engineered for once-weekly subcutaneous injection with comparable convenience to other modern GLP-1 drugs. Mechanistically, it sits in the same family as survodutide (Boehringer/Zealand) — GLP-1 / glucagon dual agonism without GIP — but with different specific receptor-binding profiles and different development positioning.

Why MASH, not obesity

The differentiating strategic decision Altimmune has made is to position pemvidutide primarily as a MASH treatment rather than a pure obesity drug. MASH — metabolic dysfunction-associated steatohepatitis, the renamed and refined version of NASH — affects roughly 5% of adults globally and is the fastest-growing cause of liver transplantation. The first FDA-approved MASH drug was resmetirom (2024), a thyroid hormone receptor agonist; pemvidutide would represent a different therapeutic mechanism for the same disease.

The MASH-first positioning makes commercial sense for Altimmune specifically. As a small biotech competing against Boehringer Ingelheim and Eli Lilly in obesity, Altimmune cannot match their resources for a head-to-head obesity Phase 3 program at full scale. A focused MASH indication, where the patient population is smaller but the medical need is acute, plays to a small-company strength.

Phase 2 results

The Phase 2 MOMENTUM-OBESITY trial of pemvidutide in adults with obesity (without diabetes) tested multiple doses against placebo over 48 weeks. Headline results:

• ~15.6% mean weight loss at 48 weeks at the highest dose (vs ~2% placebo).
• Strong liver fat reduction across all active doses, including in patients without elevated baseline liver fat.
• Tolerability qualitatively similar to other GLP-1 drugs: nausea, vomiting, constipation concentrated during titration.
• Lipid profile improvements beyond what weight loss alone would predict — consistent with glucagon's hepatic effects.

The 15.6% magnitude is meaningful but smaller than survodutide's ~19% and retatrutide's ~24%. The liver-fat-reduction story is the differentiating outcome.

The Phase 3 program

Altimmune's Phase 3 program for pemvidutide:

• MOMENTUM-MASH — the lead Phase 3 trial in MASH patients. Reading out 2026-2027.
• IMPACT — a parallel obesity Phase 3 program.

Expected approval timeline: 2027-2028 for MASH if the Phase 3 readouts are positive; obesity approval would follow on a similar timeline.

Where pemvidutide fits in the glucagon-arm family

Three Phase 3 obesity drugs incorporate the glucagon receptor. Their differences:

• Pemvidutide (Altimmune): GLP-1 / glucagon dual, ~16% Phase 2 weight loss, MASH-first positioning, small biotech.
• Survodutide (Boehringer / Zealand): GLP-1 / glucagon dual, ~19% Phase 2 weight loss, MASH and obesity parallel positioning, large pharma.
• Retatrutide (Eli Lilly): GLP-1 / GIP / glucagon triple, ~24% Phase 2 weight loss, obesity-first positioning, largest pharma in the space.

The dual-vs-triple question is the most interesting science: does adding GIP to GLP-1 + glucagon meaningfully deepen weight loss, or is the additional receptor activation incremental? See our three-way comparison for more.

The honest read

Pemvidutide is the most uncertain but most differentiated of the three glucagon-arm GLP-1 drugs. The weight-loss magnitude is the smallest of the three; the MASH focus is the sharpest. For Altimmune's investors, success depends on the MOMENTUM-MASH readout — a strong MASH outcome in a focused indication is the company's best path to approval and commercial success.

For patients in 2026-2028, pemvidutide is relevant primarily if you are tracking the MASH indication specifically. For pure obesity treatment, survodutide and retatrutide have stronger weight-loss data. For the broader field, pemvidutide is the test of whether small biotechs can compete in the GLP-1 class by picking a focused indication rather than going head-to-head on obesity with the pharma giants.